JP2024514344A5 - - Google Patents

Info

Publication number
JP2024514344A5
JP2024514344A5 JP2023564087A JP2023564087A JP2024514344A5 JP 2024514344 A5 JP2024514344 A5 JP 2024514344A5 JP 2023564087 A JP2023564087 A JP 2023564087A JP 2023564087 A JP2023564087 A JP 2023564087A JP 2024514344 A5 JP2024514344 A5 JP 2024514344A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
seq
amino acid
stable aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053733 external-priority patent/WO2022224187A1/en
Publication of JP2024514344A publication Critical patent/JP2024514344A/ja
Publication of JP2024514344A5 publication Critical patent/JP2024514344A5/ja
Pending legal-status Critical Current

Links

JP2023564087A 2021-04-21 2022-04-21 高濃度二重特異性抗体製剤 Pending JP2024514344A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163177518P 2021-04-21 2021-04-21
US63/177,518 2021-04-21
US202163180690P 2021-04-28 2021-04-28
US63/180,690 2021-04-28
US202263309230P 2022-02-11 2022-02-11
US63/309,230 2022-02-11
PCT/IB2022/053733 WO2022224187A1 (en) 2021-04-21 2022-04-21 High concentration bispecific antibody formulations

Publications (2)

Publication Number Publication Date
JP2024514344A JP2024514344A (ja) 2024-04-01
JP2024514344A5 true JP2024514344A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=81579656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564087A Pending JP2024514344A (ja) 2021-04-21 2022-04-21 高濃度二重特異性抗体製剤

Country Status (17)

Country Link
US (2) US20220395573A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326242A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514344A (cg-RX-API-DMAC7.html)
KR (1) KR20230174239A (cg-RX-API-DMAC7.html)
AU (1) AU2022260814A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021549A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217191A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230497A (cg-RX-API-DMAC7.html)
EC (1) ECSP23080283A (cg-RX-API-DMAC7.html)
IL (1) IL307879A (cg-RX-API-DMAC7.html)
JO (1) JOP20230263A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012508A (cg-RX-API-DMAC7.html)
PE (1) PE20240805A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552883A1 (cg-RX-API-DMAC7.html)
TW (1) TW202308689A (cg-RX-API-DMAC7.html)
UY (1) UY39734A (cg-RX-API-DMAC7.html)
WO (1) WO2022224187A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
CN119790073A (zh) 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025227052A1 (en) * 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases
WO2026022733A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies

Similar Documents

Publication Publication Date Title
JP6779997B2 (ja) Pd1/ctla4結合性物質
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP2024102215A5 (cg-RX-API-DMAC7.html)
JP2022532927A5 (cg-RX-API-DMAC7.html)
JP2023540025A5 (cg-RX-API-DMAC7.html)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2024544523A5 (cg-RX-API-DMAC7.html)
RU2008141433A (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2007118648A (ru) Композиции антител
RU2006120950A (ru) Антитело к cd40: препарат и способы
RU2017123972A (ru) Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
JP2025500784A5 (cg-RX-API-DMAC7.html)
JP2023504748A5 (cg-RX-API-DMAC7.html)
US20240067720A1 (en) Anti-tigit antibody pharmaceutical composition and application thereof
JP2023539589A5 (cg-RX-API-DMAC7.html)
CN110732023A (zh) 一种her2抗体药物组合物及其用途
JP2024515968A5 (cg-RX-API-DMAC7.html)
TW201907951A (zh) 用於男性及女性型態掉髮之催乳素受體抗體
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
RU2020111574A (ru) Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
JP2025500483A5 (cg-RX-API-DMAC7.html)
CN110522909A (zh) 一种协同增强抗her2阳性肿瘤效果的药物组合
WO2016045570A2 (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物